COMMUNIQUÉS West-GlobeNewswire

Minerva Neurosciences to Report Second Quarter 2017 Financial Results and Business Updates on August 3, 2017
27/07/2017
Management to host conference call WALTHAM, Mass., July 27, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat [...]
Abiomed Announces Q1 FY 2018 Revenue of $132.5 Million, Up 29% Over Prior Year
27/07/2017
Company announces Japanese reimbursement for Impella® heart pumps and raises lower end of FY 2018 revenue guidance DANVERS, Mass., July 27, 2017 (GLOBE NEWSWIRE) -- Abiomed, Inc. (NASDAQ:ABMD), a leading provider of [...]
Arix Bioscience co-leads $29 million Series A financing for PreciThera, Inc.
27/07/2017
Arix Bioscience co-leads $29 million Series A financing for PreciThera, Inc. Funding to develop novel biologics targeting orphan bone diseases into clinical trials LONDON, 27 July 2017: Arix Bioscience plc (LSE: ARIX [...]
RECORDATI: VERY GOOD RESULTS IN THE FIRST HALF 2017. CONTINUED GROWTH IN SALES +10.7%, OPERATING INCOME +19.4%, NET INCOME +19.8%
27/07/2017
Consolidated revenues € 650.9 million, +10.7%. EBITDA (1) € 224.0 million, +19.1% Operating income € 203.2 million, +19.4%. Net income € 147.0 million, +19.8%. Net financial position (2) : net debt of € 356.3 million. [...]
William Demant Holding A/S: Major shareholder announcement concerning Canada Pension Plan Investment Board
27/07/2017
Company announcement no 2017-08 27 July 2017 Major shareholder announcement concerning Canada Pension Plan Investment Board pursuant to section 29 of the Danish Securities Trading Act Pursuant to section 29 of the [...]
Bavarian Nordic Announces Additional Details Regarding the Issue of Shares to Johnson & Johnson Innovation - JJDC, Inc.
27/07/2017
COPENHAGEN, Denmark, July 27, 2017 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announces additional details regarding the issue of shares to Johnson & Johnson Innovation - JJDC, Inc. ("J&J") in connection with [...]
Bavarian Nordic Announces Agreement with Janssen for the Development of Vaccine Regimens against HIV-1 and Hepatitis B
27/07/2017
Deal builds on ongoing collaboration to develop vaccines for Human Papillomavirus (HPV) and Ebola Total potential agreement value up to $879 million USD including upfront, equity investment and milestone payments [...]
Financière de Tubize SA: 2017 half-year financial report
27/07/2017
Press release 27 July 2017 Embargo till 08:00h CET FINANCIERE DE TUBIZE SA Allée de la Recherche 60, 1070 Brussels Contact: Anne Sophie Pijcke, day-to-day management, aspijcke@icloud.com 2017 half-year financial report [...]
Financière de Tubize SA: Rapport financier semestriel 2017
27/07/2017
Communiqué de presse 27 juillet 2017 Embargo jusqu'à 08:00h CET FINANCIERE DE TUBIZE SA Allée de la Recherche 60, 1070 Bruxelles Contact: Anne Sophie Pijcke, directeur, aspijcke@icloud.com Rapport financier semestriel [...]
Nestlé reports half-year results for 2017
27/07/2017
Follow today's event live 14:00 CEST Investor call audio webcast: http://edge.media-server.com/m/go/Nestle-2017-Half-year-results/lan/en/gb_custom_2/webcastViewerEn Full details: http://www.nestle.com/media/ [...]
VALNEVA et Emergent BioSolutions joignent leurs forces pour développer un vaccin contre le virus Zika
26/07/2017
Valneva et Emergent BioSolutions joignent leurs forces pour développer un vaccin contre le virus Zika Valneva accorde une licence mondiale exclusive à Emergent pour sa technologie de production de vaccin contre le virus [...]
VALNEVA and Emergent BioSolutions Join Forces to Develop a Vaccine against the Zika Virus
26/07/2017
Valneva and Emergent BioSolutions Join Forces to Develop a Vaccine against the Zika Virus Valneva grants Emergent an exclusive worldwide license for its Zika vaccine technology (ZIKV) Valneva and Emergent will co- [...]
Oriola Corporation - Repurchase of own shares on 26 July 2017
26/07/2017
ORIOLA CORPORATION STOCK EXCHANGE RELEASE 26 JULY 2017 AT 18:45 EEST In the Nasdaq Helsinki Date 26 July 2017 Exchange transaction Buy Share trading code OKDBV Amount, shares 11 922 Average price/share, EUR 3,5615 Total [...]
Navamedic ASA: Presentation of second quarter figures
26/07/2017
Navamedic ASA invites you to follow an online presentation of the second quarter 2017 figures. The presentation will be webcasted at www.navamedic.com - investor relations - presentations - webcast on Friday 28.07 2017 [...]
Apricus Biosciences Announces Corporate Update and Second Quarter 2017 Financial Results Conference Call
26/07/2017
SAN DIEGO, July 26, 2017 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that Apricus' second quarter [...]
Gap In Perceived and Actual Rates Of Prescription Stimulant Misuse, Abuse and Diversion Found Among College Students
26/07/2017
Gap In Perceived and Actual Rates Of Prescription S timulant Misuse, Abuse and Diversion Found Among College Students Preliminary analysis of data shows association between non-medical use of prescription stimulants and [...]
Midatech Pharma Plc: Completion of pre-clinical liver cancer programme
26/07/2017
26 July 2017 Midatech Pharma PLC ("Midatech", "Company" or "Group") Completion of pre-clinical liver cancer programme Midatech Pharma (AIM: MTPH, Nasdaq: MTP), the international specialty pharmaceutical company focused [...]
Verona Pharma Doses First Patients in Phase 2b Clinical Trial of RPL554 for COPD Maintenance Treatment
26/07/2017
Dose escalation trial will evaluate RPL554 in approximately 400 COPD patients LONDON, July 26, 2017 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (NASDAQ:VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical [...]
ABLYNX RECEIVES FAST TRACK DESIGNATION FROM THE FDA FOR CAPLACIZUMAB FOR THE TREATMENT OF ACQUIRED TTP
26/07/2017
GHENT, Belgium, 26 July 2017 - Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for caplacizumab, the Company's first-in- [...]

Pages